Revised criteria for the diagnosis and staging of Alzheimer's disease

Affiliations

• ¹ Department of Radiology, Mayo Clinic, Rochester, MN, USA. jack.clifford@mayo.edu.
• ² Global Evidence & Outcomes, Takeda Pharmaceuticals Company Limited, Cambridge, MA, USA.
• ³ Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA.
• ⁴ Office of Neuroscience, US Food and Drug Administration, Silver Spring, MD, USA.
• ⁵ The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA.
• ⁶ Neuroscience Global Drug Development, Novartis, Basel, Switzerland.
• ⁷ Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
• ⁸ Memory Clinic, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden.
• ⁹ Denali Therapeutics, South San Francisco, CA, USA.
• ¹⁰ School of Public Health and Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.
• ¹¹ Department of Neurology, Washington University St Louis School of Medicine, St Louis, MO, USA.
• ¹² Experimental Medicine, Department Global Clinical Development H. Lundbeck A/S, Copenhagen, Denmark.
• ¹³ Department of Medicine, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine, Madison, WI, USA.
• ¹⁴ University of Miami, Miami, FL, USA.
• ¹⁵ Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine at the University of Southern California, San Diego, CA, USA.
• ¹⁶ Department of Neurology, Amsterdam University Medical Center (Emeritus), Amsterdam, The Netherlands.
• ¹⁷ Clinical Research, Acumen Pharmaceuticals, Zionsville, IN, USA.
• ¹⁸ Medical & Scientific Relations Division, Alzheimer's Association, Chicago, IL, USA.
• ¹⁹ Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
• ²⁰ Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Amsterdam, The Netherlands.